
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is positioned favorably within the rapidly expanding contract research organization (CRO) market, driven by long-term industry trends such as pharmaceutical vendor consolidation and increasing trial outsourcing. The company's strategic acquisition of PRA has enhanced its capabilities in early-phase trials and coupled with a robust service mix, allows it to navigate funding environment uncertainties effectively. Additionally, Icon's commitment to gender parity at senior levels reinforces its organizational strength, which, alongside anticipated growth in pharmaceutical R&D budgets, is likely to contribute positively to its revenue growth trajectory.
Bears say
Icon faces challenges stemming from a slower-than-anticipated recovery in the biotechnology sector, which is expected to adversely affect its revenue and growth trajectory in the near term. The negative sentiment is reinforced by a lack of impressive book-to-bill ratios, with the latest figures indicating potential difficulty in meeting investor expectations for growth in the upcoming quarters. Additionally, the company's anticipated earnings per share for 2025 show a concerning stagnation, suggesting that broader macroeconomic factors and client financial constraints could hinder its financial performance going forward.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares